SIGA TECHNOLOGIES INC

Overview

Compare with Grace Therapeutics, Inc., Cytokinetics or Amylyx Pharmaceuticals, or pick any stock.

• TickerSIGA on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersNew York, New York¹
• Incorporated inDE²
• Business address31 East 62Nd Street, New York, Ny 10065²
• Filer categoryAccelerated filer²

See how the biggest companies compare on our leaderboards

We are a commercial-stage pharmaceutical company. The Company sells its lead product, TPOXX® (“oral TPOXX®,” also known as "tecovirimat," "Tecovirimat-SIGA," or "TEPOXX (tecovirimat)" in certain international markets), to the U.S. Government and international governments (including government affiliated entities). In certain international markets, the Company may sell TPOXX® through a distributor. Additionally, the Company sells the intravenous formulation of TPOXX® ("IV TPOXX®") to the U.S. Government.³ From its latest annual report

Corporate structure

SIGA TECHNOLOGIES INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What SIGA TECHNOLOGIES INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

Our offices are located in New York, NY, and Corvallis, Oregon. In May 2017, we entered into a new 10-year lease with a related party to let 3,200 square feet in New York, NY to serve as our corporate headquarters. For more information about the lease, see Note 13. Related Party Transactions, to the consolidated financial statements.

In Corvallis, we lease approximately 10,276 square feet. Until its expiration on December 31, 2017, this facility was leased under an amended lease agreement signed in January 2007, and most recently changed through an addendum in April 2015. On November 3, 2017, we entered into a new lease for the same space which was scheduled to expire in December 2019. In the second quarter of 2019, we exercised the first renewal option which was scheduled to expire in December 2021. In the second quarter of 2021, we exercised the second renewal option, which extended the lease expiration date to December 31, 2024. In the second quarter of 2024, we entered into an additional addendum, which extended the lease expiration date to December 31, 2026.

Item 2 of the 10-K filed Mar 10, 2026.³

Leadership

Who has led SIGA TECHNOLOGIES INC, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerDiem Nguyen Jan 30, 2024 to now¹³
• Chief executive officerPhillip Louis Gomez Iii. Oct 24, 2016 to Dec 10, 2019¹⁴
• Chief executive officerEric A. Rose Md. Jul 30, 2007 to Sep 24, 2015¹⁵
• ChairEric A. Rose Md. Nov 23, 2016 to Aug 22, 2018¹⁶
• Chief financial officerDaniel J. Luckshire Feb 11, 2011 to now¹⁷
• Chief financial officerAyelet Dugary Feb 10, 2009 to Mar 9, 2009¹⁸
• Chief financial officerThomas N. Konatich Jul 30, 2007 to Apr 2, 2008¹⁹

Former names

• SIGA PHARMACEUTICALS INCMar 10, 1997 to May 25, 2000²

Timeline

1. Aug 6, 20268-K Results of operations⁵⁰
2. Jun 10, 20268-K Executive or director change; Shareholder vote⁵¹
3. May 7, 20268-K Results of operations⁵²
4. Mar 26, 20268-K Other events⁵³
5. Mar 10, 20268-K Results of operations⁵⁴
6. Nov 6, 20258-K Results of operations⁵⁵
7. Aug 5, 20258-K Results of operations⁵⁶
8. Jun 12, 20258-K Bylaws or fiscal year changed; Shareholder vote⁵⁷
9. May 8, 20258-K Results of operations⁵⁸
10. Apr 8, 20258-K Other events⁵⁹
11. Mar 18, 20258-K Executive or director change⁶⁰
12. Mar 11, 20258-K Results of operations⁶¹
13. Jan 30, 2024New chief executive Diem Nguyen becomes CEO¹³
14. Oct 24, 2016New chief executive Phillip Louis Gomez Iii. becomes CEO¹⁴
15. Jul 30, 2007New chief executive Eric A. Rose Md. becomes CEO¹⁵

Calendar

Coming up

1. Nov 5, 2026Reports results for the quarter ending Sep/2026⁶²

When it reported results

1. Aug 6, 2026Reported quarterly or annual results⁵⁰
2. May 7, 2026Reported quarterly or annual results⁵²
3. Mar 10, 2026Reported quarterly or annual results⁵⁴
4. Nov 6, 2025Reported quarterly or annual results⁵⁵
5. Aug 5, 2025Reported quarterly or annual results⁵⁶
6. May 8, 2025Reported quarterly or annual results⁵⁸
7. Mar 11, 2025Reported quarterly or annual results⁶¹
8. Nov 7, 2024Reported quarterly or annual results⁶³

Drug trials and FDA: coming up

1. Jan 1, 2027Phase 2 trial readout expected Phase 2 trial of Tecovirimat and Smallpox and Mpox Vaccine in Smallpox: primary completion expected Jan 1, 2027 (ClinicalTrials.gov NCT04957485).⁶⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

164 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 49 major events, 70 insider forms, 9 large holders, 16 other. The latest 20:

1. Aug 6, 202610-Q EDGAR
2. Aug 6, 20268-K EDGAR
3. Jun 25, 2026S-8 EDGAR
4. Jun 10, 20264 EDGAR
5. Jun 10, 20264 EDGAR
6. Jun 10, 20264 EDGAR
7. Jun 10, 20264 EDGAR
8. Jun 10, 20264 EDGAR
9. Jun 10, 20264 EDGAR
10. Jun 10, 20264 EDGAR
11. Jun 10, 20268-K EDGAR
12. May 8, 2026DEFA14A EDGAR
13. May 7, 202610-Q EDGAR
14. May 7, 20268-K EDGAR
15. Apr 28, 2026ARS EDGAR
16. Apr 28, 2026DEFA14A EDGAR
17. Apr 28, 2026DEF 14A EDGAR
18. Mar 26, 20264 EDGAR
19. Mar 26, 20268-K EDGAR
20. Mar 17, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• BlackRockSCHEDULE 13G/A, 5 filings Feb 1, 2022 to Apr 25, 2025⁶⁵
• John Latane Lewis Iv.SC 13G, 1 filing Feb 1, 2024⁶⁶
• D. E. SHAW & CO, L.P.SC 13G/A, 2 filings Jun 24, 2022 to Feb 14, 2023⁶⁷
• ESOPUS CREEK VALUE SERIES FUND LP - SERIES ASC 13D/A, 1 filing Nov 22, 2021⁶⁸

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Federal awards

Obligated amounts from USAspending.gov⁷⁰, by calendar year, 2008–2026, for its registration. Obligations are what agencies committed, not always what was paid out. Contracts pay for goods and services; grants, loans and direct payments are assistance. Loans are charted at the face value of the loans listed here. An award’s amount below is its lifetime total, and some began before the years charted.

Largest grants

1. May 3, 2011$5.8M from National Institutes of Health: Allergy And Infectious Diseases Research; Allergy, Immunology And Transplantation Research⁷¹ To SIGA TECHNOLOGIES, INC. Award R01AI093356
2. Aug 1, 2007$3.0M from National Institutes of Health: Allergy, Immunology And Transplantation Research⁷² To SIGA TECHNOLOGIES, INC. Award R44AI075747
3. Sep 23, 2009$1.7M from National Institutes of Health: Trans-Nih Recovery Act Research Support⁷³ To SIGA TECHNOLOGIES, INC. Award U01AI082108
4. Aug 18, 2008$963.7K from National Institutes of Health: Allergy, Immunology And Transplantation Research⁷⁴ To SIGA TECHNOLOGIES, INC. Award R43AI079937

Largest contracts

1. Sep 10, 2018$626.5M from Office of Assistant Secretary for Preparedness and Response: Procurement and late-stage development of smallpox antiviral drug(s) igf::ot::igf⁷⁵ To SIGA TECHNOLOGIES, INC. Award 75A50118C00019
2. May 13, 2011$518.5M from Office of Assistant Secretary for Preparedness and Response: Drugs and biologicals⁷⁶ To SIGA TECHNOLOGIES, INC. Award HHSO100201100001C
3. Sep 1, 2008$39.3M from Office of Assistant Secretary for Preparedness and Response: Contract award hhsn272200800041c under baa nih-niaid-dmid-08-20⁷⁷ To SIGA TECHNOLOGIES, INC. Award HHSN272200800041C
4. Sep 26, 2006$29.0M from National Institutes of Health: R&d-other svc & develop-adv dev⁷⁸ To SIGA TECHNOLOGIES, INC. Award HHSN266200600014C
5. Sep 28, 2022$11.8M from Department of the Army: Procure up to 23000 tpoxx courses for small pox treatment.⁷⁹ To SIGA TECHNOLOGIES, INC. Award W911SR22C0051

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How SIGA TECHNOLOGIES INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARSIGA TECHNOLOGIES INC¹
• CIK0001010086
• Employer ID (EIN)13-3864870³
• Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address31 East 62Nd Street, New York, NY 10065¹
• Phone212-672-9100¹
• Shares outstanding71,849,716 as of Jul 24, 2026¹⁰
• Public float$302.2M as of Jun 30, 2025³
• AuditorPricewaterhouseCoopers LLP, Florham Park, New Jersey PCAOB ID 238; it also attests to the company’s internal control over financial reporting³
• On EDGAR sinceMar 10, 1997¹
• Filings1,112 in all: 4 (449), 8-K (218), 10-Q (72), 3 (40), SC 13G/A (37), SC 13D/A (31), DEF 14A (30), SC 13G (28)¹
  All 51 form types

  10-K (24), 424B3 (18), UPLOAD (17), 10QSB (15), CORRESP (15), S-3 (13), CT ORDER (10), S-3/A (9), S-8 (7), 4/A (6), PRE 14A (6), SC 13D (6), DEFA14A (5), PRER14A (5), 10-Q/A (4), 10KSB (4), 8-K/A (4), ARS (4), EFFECT (4), S-1/A (4), SB-2/A (3), 10-K/A (2), SEC STAFF LETTER (2), 10KSB/A (1), 10KSB40 (1), 10KSB40/A (1), 10QSB/A (1), 25-NSE (1), 424B1 (1), 424B2 (1), 8-A12B (1), 8-A12G (1), CERT (1), FWP (1), NT 10-K (1), NT 10-Q (1), POS AM (1), PREM14A (1), S-1 (1), SB-2 (1), SB-2MEF (1), SC 14F1 (1), SCHEDULE 13G/A (1)

• Latest filingsAnnual report (10-K) Mar 10, 2026
  Quarterly report (10-Q) Aug 6, 2026
  Proxy statement (DEF 14A) Apr 28, 2026
  Latest 8-K (8-K) Aug 6, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 10, 2026 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks SIGA TECHNOLOGIES INC names in Item 1A of its 10-K filed Mar 10, 2026: 37 risks under these headings, as written.³

• Risks Related to Our Dependence on Government Contracts
• We expect a substantial percentage of our future operating revenues to come from contracts with the U.S. Government for the provision and maintenance of the stockpile of TPOXX® built under the 19C BARDA Contract. If the U.S. Government does not enter into such a contract, or if such contract is materially delayed or smaller than the 19C BARDA Contract, our long-term business, financial condition and operating results could be materially harmed.
• Government contracts require ongoing funding decisions by governments. A substantial percentage of our potential future revenues are expected to come from government contracts. The majority of potential revenue under any future U.S. Government contract will likely be tied to options that may or may not be exercised at the sole discretion of the U.S. Government. Failure of the U.S. Government to exercise its options under a new procurement contract to supply TPOXX® to the U.S. Government could cause our business, financial condition, results of operations and prospects to be materially harmed.
• Government procurement contracts are mostly set at fixed prices determined at inception of the contract based on estimates of the time, resources and expenses required to perform these contracts. If our estimates are not accurate, we may not be able to earn an adequate return or may incur a loss under these arrangements.
• Laws and regulations affecting government contracts and grants might make it more costly and difficult for us to successfully conduct our business.
• Unfavorable provisions in government contracts and grants, some of which may be customary, may harm our future business, financial condition and potential operating results.
• A U.S. Government shutdown could materially adversely affect our business, results of operations, and financial condition.
• Our business could be adversely affected by a negative audit by the U.S. Government.
• Risks Related to Regulatory Approvals
• If we are not able to obtain regulatory approvals for certain additional indications of TPOXX® from the FDA, we may not be able to realize the full benefits of any U.S. Government contracts or may not be able to commercialize such indications other than through existing sales to the U.S. Government, and our ability to generate future revenue could be materially impaired.
• Failure to obtain regulatory approval for new formulations of TPOXX® in the U.S. would prevent us from commercializing TPOXX® in other than the oral and intravenous formulations for smallpox treatment.
• Failure to maintain existing regulatory approvals or obtain future regulatory approvals in additional international jurisdictions could prevent us from marketing our products in certain jurisdictions abroad.

Legal proceedings

From time to time, we may be involved in a variety of claims, suits, investigations and proceedings arising from the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although such claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, we believe that the resolution of such current pending matters, if any, will not have a material adverse effect on our business, consolidated financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on us because of legal costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.³